TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00939705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study: NCT06370299

Intervention type: OTHER
Intervention: (exposure of) MDR carriage
Description: The difference in exposure between the two groups is the carriage or non-carriage of multidrug resistant gram negative bacilli.
Study: NCT04897971

Intervention type: DIAGNOSTIC_TEST
Intervention: Medium enriched for newly synthesized antibodies in spine infection
Description: Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
Study: NCT05114226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
Study: NCT06245616

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of olive pomace olive oil by alzheimer's patients
Description: Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of olive pomace olive oil by alzheimer's patients
Description: Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of high-oleic sunflower oil by alzheimer's patients
Description: Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of high-oleic sunflower oil by alzheimer's patients
Description: Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
Study: NCT04938895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Respondents Exposure to a Photo
Description: Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Respondents Exposure to a Photo
Description: Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Respondents Exposure to a Photo
Description: Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
Study: NCT04797247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: PCSK9 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lerodalcibep
Description: PCSK9 inhibitor
Study: NCT06255665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-79032421
Description: JNJ-79032421 will be administered.
Study: NCT05837559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Description: Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Description: Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
Study: NCT06306495

Intervention type: OTHER
Intervention: International Physical Activity Survey
Description: Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
Study: NCT05729256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Intervention
Description: Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice and Information
Description: Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
Study: NCT05332561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: Arm 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Arm 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Arm 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab/pertuzumab
Description: Arm 6
Study: NCT05357560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M with RH5.2 VLP and/or R21
Description: 3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
Study: NCT05816733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
Study: NCT06255665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-79032421
Description: JNJ-79032421 will be administered at RP2D regimen.
Study: NCT05945927

Intervention type: DRUG
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
Study: NCT06533904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Cryoablation of Intercostal Nerves
Description: Percutaneous Cryoablation of Intercostal Nerves

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multi-modal pain regimen
Description: Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-modal pain regimen
Description: Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
Study: NCT06542042

Intervention type: DIAGNOSTIC_TEST
Intervention: NAS, NGS and Laboratory tests
Description: Using three diffrent detection methods and comparing their efficiency

Intervention type: DIAGNOSTIC_TEST
Intervention: NAS, NGS and Laboratory tests
Description: Using three diffrent detection methods and comparing their efficiency

Intervention type: DIAGNOSTIC_TEST
Intervention: NAS, NGS and Laboratory tests
Description: Using three diffrent detection methods and comparing their efficiency
Study: NCT05727605

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test
Description: Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI
Description: Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Toxicity scoring
Description: During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
Study: NCT05499923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Debonding
Description: Debonding of orthodontic brackets with wing or base method with a conventional debonding plier

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Debonding
Description: Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
Study: NCT06281548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESTART
Description: Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
Study: NCT05692921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Home Monitoring (RHM)
Description: A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Response Nursing
Description: A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
Study: NCT04619433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
Description: Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camrelizumab;Pemetrexed and Carboplatin;Placebo
Description: Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
Study: NCT05385263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion\<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
Study: NCT06577909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: IVIg 400mg/kg (≤20g for the total dose) per day for 5 days, and repeated in the case of lack of response by day 14
Study: NCT05443555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
Study: NCT05454423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication
Description: -Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional physical therapy + anti-hyperuricemia medication
Description: traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17.
Study: NCT05433337

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital ACT
Description: Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
Study: NCT06575803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical measurements and evaluation
Description: clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics
Study: NCT06574750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)
Description: Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JuvedermⓇ (Q-Med AB, Uppsala, Sweden)
Description: Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
Study: NCT06574711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil yogurt
Description: Sacha inchi oil was incorporated into a nonfat yogurt acting as a source of linolenic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid palm oil yogurt
Description: Interspecific hybrid palm oil was incorporated into a nonfat yogurt as a source of bioactive compounds

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control yogurt
Description: Conventional full-fat yogurt
Study: NCT05858580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bennett Kids PowerUP Project
Description: Information targeting dietary and activity behaviors while also identifying and addressing barriers to permanent lifestyle change. The foundation of the curriculum is the Diabetes Prevention Program Lifestyle Balance and its subsequent adaptations for non-Native adult, Native adult, and Native child populations.
Study: NCT04730596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline in a labeled syringe
Study: NCT04927780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV